NASDAQ:IRMD IRadimed - IRMD Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding IRadimed Co. Please log in to your account or sign up in order to add this asset to your watchlist. $35.92 -1.43 (-3.83%) (As of 02/8/2023 05:18 PM ET) Add Compare Share Share Today's Range$35.34▼$37.8450-Day Range$27.80▼$42.1452-Week Range$26.00▼$55.92Volume78,539 shsAverage Volume44,163 shsMarket Capitalization$451.51 millionP/E Ratio35.22Dividend YieldN/APrice Target$48.00 ProfileAnalyst RatingsChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability IRadimed MarketRank™ ForecastAnalyst RatingN/A0.00 Rating ScoreUpside/Downside34.1% Upside$48.00 Price TargetShort InterestN/ADividend StrengthN/ASustainability-0.85Upright™ Environmental ScoreNews Sentiment0.40Based on 6 Articles This WeekInsider TradingSelling Shares$28,550 Sold Last QuarterProj. Earnings Growth17.09%From $1.17 to $1.37 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.56 out of 5 starsMedical Sector81st out of 1,029 stocksSurgical & Medical Instruments Industry8th out of 105 stocks 2.0 Analyst's Opinion Price Target Upside/DownsideAccording to analysts' consensus price target of $48.00, IRadimed has a forecasted upside of 34.1% from its current price of $35.80.Amount of Analyst CoverageIRadimed has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for IRMD. Previous Next 0.0 Dividend Strength Dividend YieldIRadimed does not currently pay a dividend.Dividend GrowthIRadimed does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIRadimed has received a 67.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Real-time vital parameter monitors for MRI machines", "Intravenous therapy equipment for MRI machines", and "ECG monitors" products. See details.Environmental SustainabilityThe Environmental Impact score for IRadimed is -0.85. Previous Next 3.0 News and Social Media Coverage News SentimentIRadimed has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for IRadimed this week, compared to 2 articles on an average week.Search Interest3 people have searched for IRMD on MarketBeat in the last 30 days. MarketBeat Follows4 people have added IRadimed to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, IRadimed insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $28,550.00 in company stock.Percentage Held by Insiders43.70% of the stock of IRadimed is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions50.03% of the stock of IRadimed is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for IRadimed are expected to grow by 17.09% in the coming year, from $1.17 to $1.37 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IRadimed is 35.10, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 140.16.Price to Earnings Ratio vs. SectorThe P/E ratio of IRadimed is 35.10, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 110.86.Price to Book Value per Share RatioIRadimed has a P/B Ratio of 6.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About IRadimed (NASDAQ:IRMD) StockIRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging (MRI) compatible medical devices. It also provides non-magnetic Intravenous (IV) infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.Read More Receive IRMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IRadimed and its competitors with MarketBeat's FREE daily newsletter. Email Address IRMD Stock News HeadlinesFebruary 6, 2023 | finance.yahoo.comWinter Springs MRI tech firm Iradimed buys Orlando land for new manufacturing plantFebruary 6, 2023 | americanbankingnews.comIRadimed (NASDAQ:IRMD) PT Raised to $48.00February 8, 2023 | Tradewins (Ad)New Years, New Ways To Trade!If you’ve been considering options trading but don’t know where to start, trading champion Chuck Hughes’ coveted guide, “Options Trading Made Easy” is for you! Free for a limited time, this guide could help 2023 become your most profitable year yet! Click here for a free copy now! February 2, 2023 | finance.yahoo.comIRadimed (IRMD) Q4 Earnings Top EstimatesFebruary 1, 2023 | americanbankingnews.comIRadimed (IRMD) Scheduled to Post Quarterly Earnings on ThursdayJanuary 26, 2023 | finance.yahoo.comIRADIMED CORPORATION to Hold 2022 Fourth Quarter Financial Results Conference Call on February 2ndJanuary 20, 2023 | finance.yahoo.comShareholders Would Enjoy A Repeat Of IRadimed's (NASDAQ:IRMD) Recent Growth In ReturnsJanuary 18, 2023 | finance.yahoo.comIRADIMED CORPORATION Announces Preliminary Financial Results for Fourth Quarter 2022February 8, 2023 | Tradewins (Ad)New Years, New Ways To Trade!If you’ve been considering options trading but don’t know where to start, trading champion Chuck Hughes’ coveted guide, “Options Trading Made Easy” is for you! Free for a limited time, this guide could help 2023 become your most profitable year yet! Click here for a free copy now! January 6, 2023 | finance.yahoo.comShould You Be Adding IRadimed (NASDAQ:IRMD) To Your Watchlist Today?January 3, 2023 | reuters.comIRMD.A - Iradimed Corp | Stock Price & Latest News | ReutersDecember 7, 2022 | finance.yahoo.comWill Weakness in IRadimed Corporation's (NASDAQ:IRMD) Stock Prove Temporary Given Strong Fundamentals?November 29, 2022 | finance.yahoo.comHere is Why Growth Investors Should Buy iRadimed (IRMD) NowNovember 9, 2022 | finance.yahoo.comIRadimed Third Quarter 2022 Earnings: Beats ExpectationsNovember 7, 2022 | finance.yahoo.comInvesting in IRadimed (NASDAQ:IRMD) five years ago would have delivered you a 113% gainNovember 3, 2022 | finance.yahoo.comIRADIMED CORPORATION Announces Third Quarter 2022 Financial ResultsOctober 27, 2022 | finance.yahoo.comIRADIMED CORPORATION to Hold 2022 Third Quarter Financial Results Conference Call on November 3rdOctober 18, 2022 | finance.yahoo.comIn spite of recent selling, insiders still control 43% of IRadimed Corporation (NASDAQ:IRMD)October 17, 2022 | benzinga.com2022 Infusion Pumps and Devices Technology and Global Markets Report with Profiles of Leading Players - I - BenzingaOctober 15, 2022 | nasdaq.comShould You Think About Buying IRadimed Corporation (NASDAQ:IRMD) Now? - NasdaqOctober 10, 2022 | finance.yahoo.com3 REITs With Dividends Above 8% - Yahoo FinanceOctober 10, 2022 | finance.yahoo.comIradimed Withdraws FDA Application For Updated MR IV Pump SystemOctober 10, 2022 | globenewswire.comIRADIMED CORPORATION Withdraws 510(k) with Plans to Resubmit After Further Discussions with FDA - GlobeNewswireOctober 10, 2022 | finance.yahoo.comIRADIMED CORPORATION Withdraws 510(k) with Plans to Resubmit After Further Discussions with FDAOctober 7, 2022 | benzinga.comIRADIMED CORPORATION Announces Appointment of Hilda Scharen-Guivel to Board of Directors - iRadimed (NASD - BenzingaOctober 6, 2022 | finance.yahoo.comIRADIMED CORPORATION Announces Appointment of Hilda Scharen-Guivel to Board of DirectorsSeptember 24, 2022 | nasdaq.comValidea Motley Fool Strategy Daily Upgrade Report - 9/24/2022 - NasdaqSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive IRMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IRadimed and its competitors with MarketBeat's FREE daily newsletter. Email Address IRMD Company Calendar Last Earnings10/28/2021Today2/08/2023Ex-Dividend for 2/21 Dividend2/10/2023Dividend Payable2/21/2023Next Earnings (Estimated)5/05/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IRMD CUSIPN/A CIK1325618 Webwww.iradimed.com Phone(407) 677-8022Fax407-677-5037Employees110Year FoundedN/APrice Target and Rating Average Stock Price Forecast$48.00 High Stock Price Forecast$48.00 Low Stock Price Forecast$48.00 Forecasted Upside/Downside+33.6%Consensus RatingN/A Rating Score (0-4)0.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)$1.02 Trailing P/E Ratio35.22 Forward P/E Ratio30.70 P/E GrowthN/ANet Income$12.83 million Net Margins23.99% Pretax Margin29.00% Return on Equity19.35% Return on Assets16.85% Debt Debt-to-Equity RatioN/A Current Ratio12.82 Quick Ratio11.89 Sales & Book Value Annual Sales$53.30 million Price / Sales8.47 Cash Flow$0.78 per share Price / Cash Flow45.91 Book Value$5.85 per share Price / Book6.14Miscellaneous Outstanding Shares12,570,000Free Float7,075,000Market Cap$451.51 million OptionableNot Optionable Beta1.07 Key ExecutivesRoger SusiChairman, President & Chief Executive OfficerJohn F. GlennChief Financial OfficerChris WilliamsonVice President-Information TechnologyLynn NeuhardtVice President-Research & DevelopmentRandy WaddellVP-Worldwide Sales & MarketingKey CompetitorsApollo EndosurgeryNASDAQ:APENAnika TherapeuticsNASDAQ:ANIKMiMedx GroupNASDAQ:MDXGOrthofix MedicalNASDAQ:OFIXAngioDynamicsNASDAQ:ANGOView All CompetitorsInsiders & InstitutionsRussell Investments Group Ltd.Sold 55,740 shares on 2/8/2023Ownership: 1.611%Los Angeles Capital Management LLCBought 3,120 shares on 2/6/2023Ownership: 0.102%Navellier & Associates Inc.Bought 1,045 shares on 2/2/2023Ownership: 0.074%Rice Hall James & Associates LLCSold 2,968 shares on 1/27/2023Ownership: 0.583%Calamos Advisors LLCSold 60,105 shares on 1/26/2023Ownership: 0.101%View All Insider TransactionsView All Institutional Transactions IRMD Stock - Frequently Asked Questions What is IRadimed's stock price forecast for 2023? 0 Wall Street research analysts have issued 1 year price objectives for IRadimed's stock. Their IRMD share price forecasts range from $48.00 to $48.00. On average, they predict the company's stock price to reach $48.00 in the next year. This suggests a possible upside of 28.5% from the stock's current price. View analysts price targets for IRMD or view top-rated stocks among Wall Street analysts. How have IRMD shares performed in 2023? IRadimed's stock was trading at $28.29 at the beginning of 2023. Since then, IRMD stock has increased by 32.0% and is now trading at $37.35. View the best growth stocks for 2023 here. When is IRadimed's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 5th 2023. View our IRMD earnings forecast. How were IRadimed's earnings last quarter? IRadimed Co. (NASDAQ:IRMD) announced its quarterly earnings results on Thursday, October, 28th. The medical equipment provider reported $0.23 EPS for the quarter, topping analysts' consensus estimates of $0.17 by $0.06. The medical equipment provider earned $10.91 million during the quarter, compared to the consensus estimate of $10.39 million. IRadimed had a trailing twelve-month return on equity of 19.35% and a net margin of 23.99%. During the same period last year, the company earned $0.09 EPS. How often does IRadimed pay dividends? What is the dividend yield for IRadimed? IRadimed declared a dividend on Monday, February 6th. Shareholders of record on Monday, February 13th will be given a dividend of $1.05 per share on Tuesday, February 21st. This represents a dividend yield of 2.54%. The ex-dividend date of this dividend is Friday, February 10th. This is a positive change from the stock's previous dividend of $1.00. Read our dividend analysis for IRMD. What guidance has IRadimed issued on next quarter's earnings? IRadimed issued an update on its fourth quarter 2022 earnings guidance on Wednesday, January, 18th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $14.90 million-$14.90 million, compared to the consensus revenue estimate of $14.63 million. What other stocks do shareholders of IRadimed own? Based on aggregate information from My MarketBeat watchlists, some companies that other IRadimed investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Alphabet (GOOG), Mastercard (MA), Micron Technology (MU), PayPal (PYPL), CRISPR Therapeutics (CRSP), IntriCon (IIN), QUALCOMM (QCOM) and Twitter (TWTR). What is IRadimed's stock symbol? IRadimed trades on the NASDAQ under the ticker symbol "IRMD." Who are IRadimed's major shareholders? IRadimed's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Russell Investments Group Ltd. (1.61%), Rice Hall James & Associates LLC (0.58%), Los Angeles Capital Management LLC (0.10%), Calamos Advisors LLC (0.10%), Navellier & Associates Inc. (0.07%) and Allspring Global Investments Holdings LLC (0.02%). Insiders that own company stock include Anthony Vuoto, Brent Johnson, Christopher K Scott, James B Hawkins, Louis S Waldman, Monty K Allen, Monty K Allen and Roger E Susi. View institutional ownership trends. How do I buy shares of IRadimed? Shares of IRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is IRadimed's stock price today? One share of IRMD stock can currently be purchased for approximately $37.35. How much money does IRadimed make? IRadimed (NASDAQ:IRMD) has a market capitalization of $469.49 million and generates $53.30 million in revenue each year. The medical equipment provider earns $12.83 million in net income (profit) each year or $1.02 on an earnings per share basis. How many employees does IRadimed have? The company employs 110 workers across the globe. How can I contact IRadimed? IRadimed's mailing address is 1025 Willa Springs Dr., Winter Springs FL, 32708. The official website for the company is www.iradimed.com. The medical equipment provider can be reached via phone at (407) 677-8022, via email at investorrelations@iradimed.com, or via fax at 407-677-5037. This page (NASDAQ:IRMD) was last updated on 2/8/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.